- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00254982
Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)
9. oktober 2015 oppdatert av: Merck Sharp & Dohme LLC
An Open-Label Study to Determine Equivalence in Efficacy, Organ Safety and Systemic Tolerability Between Infliximab in GROUP I ("High Need") and GROUP II ("Low Need") Patients Suffering From Chronic Plaque Psoriasis (Psoriasis Vulgaris)
This is an open-label, multicenter, parallel-group comparison study of the efficacy, safety, and tolerability of infliximab therapy in adult patients suffering from chronic plaque psoriasis (psoriasis vulgaris).
Patients will be assigned to GROUP I ("high need") or GROUP II ("low-need") by the investigator according to their previous psoriasis treatment.
Studieoversikt
Studietype
Intervensjonell
Registrering (Faktiske)
593
Fase
- Fase 3
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Written informed consent by the patient for study participation, prior to protocol specific procedures.
- Patients who are 18 years of age or older at time of enrollment, may be male or female and of any race.
- Diagnosis of plaque-type psoriasis (psoriasis vulgaris) at least 6 months prior to screening.
- Plaque-type psoriasis covering at least 10% of total body surface area.
- Psoriasis Area and Severity Index (PASI)-Score of 12 or greater.
- GROUP I ("high need") patients: adult patients with moderate to severe plaque psoriasis who are either not controlled by, or are intolerant to or have contraindications to at least two currently available systemic therapies (e.g. photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept). GROUP II ("low need") patients: adult patients with moderate to severe plaque psoriasis who have undergone pre-treatment with no more than one currently available systemic therapy (e.g. photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept). A patient showing contraindications towards two systemic treatments, who has never been pretreated with a systemic therapy will be assigned to GROUP II ("low need").
- Patients must have had a chest x-ray (preferably posteroanterior and lateral) within 3 months prior to first infusion with no evidence of malignancy, infection (e.g. tuberculosis) or fibrosis.
- Laboratory test results: liver enzymes (aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT) and alkaline phosphatase) must be within 1.5 times the upper limit of normal range (ULN), total bilirubin <=1.0 ULN, serum creatinine <1.5 mg/dL (must be available at Baseline).
- Patients must agree to avoid prolonged sun exposure or other ultraviolet light sources during the study.
- Women of child-bearing potential must agree to use a medically accepted method of contraception prior to screening, while receiving protocol-specified medication, and for six months after stopping the medication. Acceptable methods of contraception include abstinence, condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device (IUD), oral or injectable hormonal contraceptive, and surgical sterilization (e.g. hysterectomy or tubal ligation).
- Women of child-bearing potential must have a negative serum pregnancy test (beta-human chorionic gonadotropin [hCG]) at Screening (must be available at Baseline).
- Baseline PASI-Score of 12 or greater.
Exclusion Criteria:
- Patients suffering from active or latent tuberculosis. Prior to the start of treatment with infliximab tuberculosis needs to be excluded following the recommendations published by the German Paul Ehrlich Institute.
- Patients who have had or have a serious infection (e.g. abscess, pneumonia or pyelonephritis) or who have been hospitalized or received treatment with intravenous antibiotics during the previous 2 months.
- Patients who are known to be infected with human immunodeficiency virus, hepatitis B or C virus, prior or current opportunistic infections (within the last six months, Herpes zoster within the last 2 months).
- Patients suffering from congestive heart failure including medically controlled asymptomatic patients.
- History of demyelinating disease or symptoms suggestive of multiple sclerosis or optic neuritis.
- Patients who have current signs and symptoms or history of systemic lupus erythematosus.
- Patients suffering from non-plaque psoriasis, e.g. erythrodermic, guttate or pustular forms. The presence of psoriasis-arthritis is no exclusion criterion.
- Patients suffering from current drug induced psoriasis (e.g. a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers or calcium-channel-blockers). If the patient takes one of those substances on a regular basis, it should be on a stable dose for at least three weeks prior to Baseline.
- Patients suffering from severe, progressive or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral or psychiatric diseases, that, in the opinion of the investigator, would interfere with the study evaluations or safe or optimal participation in the study.
- Any known malignancy during the last five years (except basal cell carcinoma), any history of lymphoproliferative disease.
- Patients who have received any systemic psoriasis therapy (e.g. immunosuppressant) or lithium within 28 days or baseline visit.
- Patients pretreated with etanercept or efalizumab within 28 days of Baseline.
- Patients previously treated with infliximab.
- Patients who have used topical treatments that could affect PASI evaluation (e.g. corticosteroids, anthralin, topical vitamin D derivates) within 2 weeks of baseline visit, except special areas like head or hands.
- Patients who have used any investigational drug within 3 months of Baseline.
- Patients with allergy/sensitivity to study drug or its excipients.
- Women who are breast-feeding, pregnant, or intend to become pregnant.
- Patients with any clinically significant condition or situation, other than the condition being studied.
- Patients who are participating in any other clinical study.
- Patients who are part of the staff personnel directly involved with this study.
- Patients who are a family member of the investigational study staff.
- Patients who have used any investigational drug within 3 months before Baseline.
- Patients who have received any systemic psoriasis therapy (e.g. immunosuppressants) or lithium within 28 days of baseline visit.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Group 1 (high-need)
Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
|
Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
Andre navn:
|
Eksperimentell: Group II (low-need)
Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
|
Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Proportion of Participants Achieving a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score
Tidsramme: Baseline and Week 22
|
PASI75 response is defined as participants who achieved at least a 75% improvement in PASI score from Baseline to Week 22.
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their responses to therapy.
The PASI produces a numeric score that can range from 0 to 72 (the higher the number, the worse the disease).
|
Baseline and Week 22
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. august 2005
Primær fullføring (Faktiske)
1. september 2006
Studiet fullført (Faktiske)
1. september 2006
Datoer for studieregistrering
Først innsendt
15. november 2005
Først innsendt som oppfylte QC-kriteriene
16. november 2005
Først lagt ut (Anslag)
17. november 2005
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
12. oktober 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
9. oktober 2015
Sist bekreftet
1. oktober 2015
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P04320
- 2005-001243-28 (EudraCT-nummer)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Psoriasis
-
ProgenaBiomeRekrutteringPsoriasis | Psoriasis Vulgaris | Psoriasis i hodebunnen | Psoriatisk plakk | Psoriasis Universalis | Psoriasis ansikt | Psoriasis negl | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaForente stater
-
Clin4allRekrutteringPsoriasis i hodebunnen | Psoriasis negl | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrankrike
-
Centre of Evidence of the French Society of DermatologyRekrutteringPsoriasis | Psoriasis Vulgaris | Psoriasis i hodebunnen | Psoriatisk plakk | Psoriasis Universalis | Psoriasis Palmaris | Psoriatisk erytrodermi | Psoriasis negl | Psoriasis Guttate | Psoriasis invers | Psoriasis pustulærFrankrike
-
AmgenFullførtPsoriasis-type psoriasis | Plakk-type psoriasisForente stater
-
Innovaderm Research Inc.FullførtPsoriasis i hodebunnen | Pustuløs Palmo-plantar Psoriasis | Ikke-pustulær Palmo-plantar Psoriasis | Psoriasis i albuen | Psoriasis i underbenetCanada
-
UCB Biopharma S.P.R.L.FullførtModerat til alvorlig psoriasis | Generalisert pustuløs psoriasis og erytrodermisk psoriasisJapan
-
TakedaRekrutteringGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
Janssen Pharmaceutical K.K.RekrutteringGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
Eli Lilly and CompanyFullførtGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
PfizerFullførtPsoriasis Vulgaris | Pustuløs psoriasis | Psoriasis Arthropathica | Erytrodermisk psoriasisJapan
Kliniske studier på Infliximab
-
Onze Lieve Vrouwe GasthuisSanteonUkjent
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupAvsluttet
-
Diakonhjemmet HospitalSouth-Eastern Norway Regional Health AuthorityFullførtLeddgikt | Crohns sykdom | Ulcerøs kolitt | Psoriasisartritt | Spondyloartritt | Psoriasis kroniskNorge
-
Centre hospitalier de l'Université de Montréal...Ottawa Hospital Research Institute; Maisonneuve-Rosemont Hospital; Niagara... og andre samarbeidspartnereRekruttering
-
PfizerFullførtPsoriasis Vulgaris | Pustuløs psoriasis | Psoriasis Arthropathica | Erytrodermisk psoriasisJapan
-
NYU Langone HealthTilbaketrukketInflammatorisk tarmsykdom
-
Epirus Biopharmaceuticals (Switzerland) GmbHUkjent
-
PfizerFullførtCrohns sykdom | Ulcerøs kolittJapan
-
Janssen Research & Development, LLCJanssen Biologics BVFullførtUlcerøs kolittForente stater, Frankrike, Storbritannia, Belgia, Sveits, Israel, Canada, Australia, Nederland, New Zealand, Østerrike, Tyskland, Danmark, Tsjekkia, Argentina
-
BiocadFullførtAnkyloserende spondylittDen russiske føderasjonen, Hviterussland